肺力咳合剂联合孟鲁司特治疗老年感染后咳嗽疗效观察

目的：评价肺力咳联合孟鲁司特治疗老年感染后咳嗽的疗效。方法：将84例感染后咳嗽的患者（日间或夜间咳嗽症状积分在3分以上者）随机分为孟鲁司特组、肺力咳组、肺力咳联合孟鲁司特组（简称联合治疗组），连用2周。在治疗前、治疗2周后分别记录患者的咳嗽症状积分，比较三组疗效和肺功能变化。结果：治疗2周后，肺力咳组、孟鲁司特组、联合治疗组咳嗽症状评分分别为（3.17±0.72）分、（2.69±0.80）分、（1.72±0.89）分，较治疗前均有降低；治疗后三组间比较，联合治疗组较肺力咳组、孟鲁司特组差异均有统计学意义（P〈0.05）。肺力咳组、孟鲁司特组、联合治疗组的有效率分别为64.3％、60.7％、89.2％，联合治疗组较肺力咳组、孟鲁司特组差异均有统计学意义（P〈0.05）。结论：孟鲁司特、肺力咳合剂对成人感染后咳嗽均有明显的疗效，并且两药联合可能具有协同作用，可为成人感染后咳嗽提供一种治疗选择。

Clinical Effect of the Feilike Heji Combined with Montelukast on Old Patients with Postinfectious Cough

Objective：To evaluate the therapeutic efficacy of montelukast and Feilike heji alone or combined use in the treatment of old patients with postinfectious cough. Method：84 adult patients with postinfectious cough（daytime and nighttime cough symptom scored 3 points or above）were randomly divided into three groups：montelukast group,Feilike heji group and montelukast combined with Feilike heji group（combination group）. Patients in each group received relevant medicine for 2 weeks respectively. All patients’cough symptom scores were recorded before and 2 weeks later after treatment. The therapeutic efficacy and lung function were compared among 3 groups. Result：The cough symptom scores of montelukast group, Feilike heji group and combination group were（3.17±0.72）,（2.69±0.80）and（1.72±0.89）,respectively,all decreased obviously after 2 weeks of treatment. The score of combination group was lower than those of montelukast group and Feilike heji group（P〈0.05）. The effective rates of montelukast group,Feilike heji group and combination group were 64.3%,60.7%,89.2%,respectively. There were statistical significance in difference between combination group and montelukast group or Feilike heji group（P〈0.05）. Conclusion：Montelukast and Feilike heji are both effective in the treatment of adult postinfectious cough,montelukast combined with Feilike heji can be a better choice for the treatment of adult postinfectious cough.